Trials / Withdrawn
WithdrawnNCT07049432
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
A Phase I Study of N-803 Maintenance Therapy Following CD19 Directed CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (CARMEN-803 Trial)
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to learn whether the study drug N-803 is safe and tolerable in patients with B-cell non-Hodgkin lymphoma who have undergone CAR T-cell therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N803 | N-803 subcutaneously (SubQ) administered on day 1 of each 21-day cycle for up to 6 cycles. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2030-12-01
- Completion
- 2031-12-01
- First posted
- 2025-07-03
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07049432. Inclusion in this directory is not an endorsement.